Singapore a top draw for Pfizer as it looks to invest for the long run


FILE PHOTO: A view of the skyline in Singapore, January 27, 2023. REUTERS/Caroline Chia/File Photo

SINGAPORE: Singapore is not a low-cost manufacturing base, but good infrastructure, respect for intellectual property, access to talent, and a government with a vision are what makes it the go-to destination for US pharma giant Pfizer.

“There are no short-term investments in the world of pharmaceuticals,” said Mike McDermott, chief global supply officer and executive vice-president of Pfizer.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Singapore , manufacturing , pharma , Pfizer

Next In Business News

Trading ideas: Binastra, Capital A, Allianz, MN, Vestland, Genting Plantations, YTL Cement, Pimpinan Ehsan, TH Plantations, Marine & General, FGV, SumiSaujana
Energy transition to propel Sarawak’s future
New tech leaves other sectors behind
Indonesia’s domestic investors dominate as FDI falters for 2025
Construction companies poised to�sustain growth
US Federal Reserve vice-chair says interest rates are well positioned
If I were an ageing oil palm tree
Hurdles in DBS’ Alliance Bank bid
Germany proposes giving EV buyers subsidies to boost demand
Metals keep shining bright

Others Also Read